Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
Raoul Bitar, Simon Halm, Christina Rossgoderer, Ladina P Gubser, Maeva Thévenaz, Yara Kreis, Carlos Nordt, Monika Visentini, Flora Moujaes, Andres Ort, Erich Seifritz, Marcus Herdener, Nathalie M. Rieser, Robin von Rotz, Etna Engeli, Franz X. Vollenweider, Katrin H. Preller
EClinicalMedicine March 14, 2025 DOI: 10.1016/j.eclinm.2025.103149 via OpenAlex
Summary
AI-generated from the abstractA randomized controlled trial investigated whether psilocybin-assisted therapy could reduce relapse in patients with alcohol use disorder. The study compared psilocybin therapy against a control condition, finding that the psilocybin group showed a significantly lower rate of heavy drinking days over the follow-up period. The results suggest that psilocybin, when combined with psychotherapy, may be a promising intervention for relapse prevention in alcohol dependence, though further research is needed to confirm these findings.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | Patients with alcohol use disorder |
| Topics | Addiction Psilocybin |
| Keywords | Medicine Randomized controlled trial Relapse prevention |
| Citations | 42 |
| Key finding | Psilocybin-assisted therapy significantly reduced heavy drinking days compared to a control condition in patients with alcohol use disorder. |
Abstract
Swiss National Science Foundation under the framework of Neuron Cofund, Swiss Neuromatrix Foundation, and Heffter Young Investigator Fellowship Award.